X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ITM-31 is a carbonic anhydrase (CA) XII-specific antibody Fab fragment, which is currently being evaluated for the treatment of glioblastoma.
Lead Product(s): Lu-177 labeled 6A10-Fab-fragments
Therapeutic Area: Oncology Product Name: ITM-31
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Isotope Technologies Munich
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2024
Details:
Under the agreement, Medigene accelerates the expansion of its end-to-end platform of multiple, combinable, exclusive and proprietary technologies with the potential to create best-in-class T cell receptor engineered T cell (TCR-T) therapies for patients with solid tumors.
Lead Product(s): TCR-T-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Medigene
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 02, 2023
Details:
Under the terms of the license agreement, ITM will hold exclusive rights to the compound ITM-31 as well as the rights to related patents and know-how for the manufacturing and use of ITM-31.
Lead Product(s): ITM-31
Therapeutic Area: Oncology Product Name: ITM-31
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Isotope Technologies Munich
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 19, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
